Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ:CERT)

11.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Certara Launches Phoenix™ Version 8.5 Drug Development Software
From Certara
Via GlobeNewswire
CERT Stock Earnings: Certara Misses EPS, Misses Revenue for Q2 2024
CERT stock results show that Certara missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Certara Reports Second Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
From Certara
Via GlobeNewswire
Decoding 4 Analyst Evaluations For Certara
 
Via Benzinga
Analyst Scoreboard: 4 Ratings For Certara
 
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Simulations Plus Stock Drops 15% Despite EPS Beat
Simulations Plus fell 15% the day after its earnings release despite beating EPS estimates due to lower margins and lower full-year guidance. 
Via MarketBeat
Topics Artificial Intelligence
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
From Certara
Via GlobeNewswire
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
AI-enabled solutions accelerate regulatory and medical writing processes, enhancing quality, transparency, and efficiencies 
From Certara
Via GlobeNewswire
Recap: Certara Q3 Earnings
 
Via Benzinga
The Latest Analyst Ratings for Certara
 
Via Benzinga
The Latest Analyst Ratings for Certara
 
Via Benzinga
Certara to Participate in the Jefferies Global Healthcare Conference
From Certara
Via GlobeNewswire
Certara Appoints New Chief Human Resources Officer & General Counsel
From Certara
Via GlobeNewswire
CERT Stock Earnings: Certara Meets EPS, Beats Revenue for Q1 2024
CERT stock results show that Certara met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Certara Reports First Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
From Certara
Via GlobeNewswire
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
From Certara
Via GlobeNewswire
Certara Reports Fourth Quarter 2023 Financial Results
Provides Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
From Certara
Via GlobeNewswire
Tax Season Is Here: Meet The New Federal Program That Can Eat Away At Tax Preparation Companies
New IRS program launching for free tax filing could affect tax prep companies like H&R Block and Intuit. Market share drop could impact ETFs. 
Via Benzinga
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
Combined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development. 
From Certara
Via GlobeNewswire
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies 
From Certara
Via GlobeNewswire
Certara Reports Third Quarter 2023 Financial Results
Reiterates Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines 
From Certara
Via GlobeNewswire
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations 
From Certara
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.